Prostate cancer progression, epithelial to mesenchymal transition and nuclear receptors
Poster Session 11
-
Location:Room Amsterdam, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session Cellular events during prostate cancer progression are controlled by transcription factors, miRNA, and nuclear receptors. Several contributions highlight the role of miRNA in different prostate cell types and show causal relationships with prostate cancer progression and stemness. These novel regulatory networks will be discussed in the session.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1University of Oxford, Nuffield Dept. of Surgical Sciences, Oxford, United Kingdom, 2University of Oxford, Nuffield Dept. of Medicine, Oxford, United Kingdom
Institutes: 1IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, 2Fondo Edo Tempia, Laboratory of Cancer Genomics, Biella, Italy, 3University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland
Institutes: 1Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, 2Leiden University Medical Center, Dept. of Urology, Leiden, The Netherlands, 3Slotervaart Medical Centre, Dept. of Orthopaedic Surgery, Amsterdam, The Netherlands, 4Academic Medical Centre, Dept. of Orthopaedic Trauma Surgery, Amsterdam, The Netherlands, 5University Hospital Bern, Dept. of Urology, Bern, Switzerland
Institutes: 1Urology Research Laboratory, Dept. of Clinical Research, Bern, Switzerland, 2Leiden University Medical Center, Urology Research Laboratory, Leiden, The Netherlands, 3University Hospital Bern, Dept. of Urology, Bern, Switzerland
Institutes: 1Idibell, Dept. of Procure, Ico, Barcelona, Spain, 2Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medica, Dept. of Urology, Medicine, Systems Biology, and Pathology and Cell Biology, New York, United States of America, 3Rutgers, Dept. of Health Informatics, Newark, United States of America, 4Center for Computational Biology and Bioinformatics, Institute of Cancer Genetics, Herbert Irving Co, Dept. of Systems Biology, Biomedical Informatics, and Biochemistry and Molecular Biophysics, New York, United States of America
Institutes: 1Salford Royal NHS Foundation Trust, Dept. of Urology, Salford, United Kingdom, 2AstraZeneca, R&D, Oncology IMed, Macclesfield, United Kingdom, 3The University of Manchester, Genito Urinary Cancer Research Group, Division of Molecular & Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, Manchester, United Kingdom, 4Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, 5Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom
Institutes: 1UZ Leuven, Dept. of Urology, Leuven, Belgium, 2KU Leuven, Dept. of Molecular and Cellular Medicine, Leuven, Belgium, 3Université Libre de Bruxelles, Dept. of Pathology, Brussels, Belgium, 4Université Libre de Bruxelles, DIAPath – Center for Microscopy and Molecular Imaging, Gosselies, Belgium
Institutes: 1Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada, 2BC Cancer Research Centre, Dept. of Pathology, Vancouver, Canada
Institutes: 1Tokushima University, Dept. Of Urology, Tokushima, Japan, 2Tokushima University, Dept. of Urology, Tokushima, Japan
Institutes: Second Affiliated Hospital Of Soochow University, Suzhou, China, Dept. of Urology, Suzhou, China